Number Needed to Vaccinate with a Novel Tuberculosis Vaccine to Prevent Tuberculosis in High-Risk Populations, United States
Rothman, J. E.; Castro, K. G.; Lopman, B.; Gandhi, N. R.; Nelson, K.
Show abstract
We estimated the number needed to vaccinate (NNV) with an M72/AS01E-like vaccine to prevent one tuberculosis case in U.S. high-risk groups. Targeted vaccination of Mycobacterium tuberculosis-infected persons yielded NNVs of 217 (persons with HIV) to 2,486 (U.S.-born), within the range of established adult vaccines.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea 94%
- Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada 94%
- Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older 93%
Similar papers in this journal
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 93%
- Burden of lower respiratory tract infections preventable by adult immunization with 15- and 20-valent pneumococcal conjugate vaccines in the United States 93%
- Cost-Effectiveness of Prefusion F Protein-Based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States 93%
Similar papers in this journal
- Health impact and cost-effectiveness of COVID-19 vaccination in Sindh Province, Pakistan 94%
- The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries 94%
- Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants 94%
Similar papers in this journal
- COVID-19 vaccine uptake and effectiveness by time since vaccination in the Western Cape province, South Africa: An observational cohort study during 2020-2022 94%
- Durability of protection post-primary COVID-19 vaccination in the US: matched case-control study 93%
- Effectiveness of ChAdOx1 nCoV-19 Corona Virus Vaccine (Covishield™) in preventing SARS-CoV2 infection, Chennai, Tamil Nadu, India, 2021 93%
Similar papers in this journal
- Optimizing next-generation RSV prevention in Mali: a cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis 93%
- Cost-effectiveness Analysis of Alternative Infant and Neonatal Rotavirus Vaccination Schedules in Malawi 93%
- Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.